Thus, while checkpoint receptors like LILRB4 can be effectively targeted to treat some cancers or revert exhausted CD8+ T cells from mice chronically infected with LCMV (71), their role in acute infection is complex and should be gauged carefully when using therapeutically. Here, LILRB4 is linked to cancer.